Grufity logoGrufity logo

VRTX

316.40USD+0.07(+0.02%)Market Closed

Vertex Pharmaceuticals Inc

Market Summary

USD316.40+0.07Market Closed
0.02%

VRTX Alerts

VRTX Stock Price

RSI Chart

Valuation

Market Cap

80.6B

Price/Earnings

24.61

Price/Sales

9.26

Price/Cashflow

19.91

MarketCap/EBT

20.01

Price/Sales

Profitability

EBT Margin

46.28%

Return on Equity

25.12%

Return on Assets

19.59%

Fundamentals

Revenue

Revenue (TTM)

8.7B

Revenue Y/Y

17.65%

Revenue Q/Q

6.29%

Earnings

Earnings (TTM)

3.3B

Earnings Y/Y

9.22%

Earnings Q/Q

14.81%

Price Action

52 Week Range

194.10323.61
(Low)(High)

Last 7 days

0.1%

Last 30 days

1.4%

Last 90 days

9.0%

Trailing 12 Months

69.3%

Financial Health

Current Ratio

4.7

Investor Care

Shares Dilution (1Y)

0.96%

Diluted EPS (TTM)

12.66

Peers (Alternatives to Vertex Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
10.10% 45.26%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
13.45% -44.87%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
0.39% 18.09%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
1.41% 69.25%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
6.43% 20.02%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
21.41% 47.70%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
7.71% 51.97%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-2.66% 8.03%
-18.85
63.29
26.15% -23.38%
3.8B
-
35.74% -33.19%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
-7.81% -50.32%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-10.28% -51.75%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
20.91% 139.57%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
-1.00% -15.23%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
25.59% -63.47%
-1.4
4.57
-43.57% -69.06%
16.0M
-
49.62% -77.48%
-0.46
19.11
-77.61% 5.14%

Financials for Vertex Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue4.2%8,7018,3507,9487,5747,130
  S&GA Expenses5.5%932884863840797
  R&D Expenses4.8%3,1983,0512,823
Earnings Before Taxes2.4%4,0273,9332,8642,7302,748
Net Income2.5%3,2733,1952,4512,3422,176
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets7.2%16,70615,58214,25613,43312,619
  Current Assets6.7%12,27111,50410,3619,5618,853
    Cash Equivalents5.4%9,1728,7027,6006,7956,276
  Inventory5.6%388368339353333
  Goodwill7.3%1,0751,0021,0021,0001,002
Liabilities0.8%3,6773,6493,3493,3333,088
  Current Liabilities2.1%2,6092,5562,1802,1421,914
Shareholder's Equity9.2%13,03011,93410,90710,1009,531
  Retained Earnings19.5%5,7044,7733,9633,2012,431
  Additional Paid-In Capital1.8%7,2267,1006,9306,8817,086
Shares Outstanding0.2%257256256254256
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations0.7%4,0464,0182,6792,6442,140
  Share Based Compensation7.0%498466457441420
Cashflow From Investing-110.7%-630.70-299.40-317.59-340.9037
Cashflow From Financing57.3%-444.13-1,040.60-1,054.75-1,478.00-1,266.98
  Buy Backs-63.6%3681,0101,0101,4251,198

Risks

What is the probability of a big loss on VRTX?

25.8%


Probability that Vertex Pharmaceuticals stock will be more than 20% underwater in next one year

6.5%


Probability that Vertex Pharmaceuticals stock will be more than 30% underwater in next one year.

0%


Probability that Vertex Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VRTX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Vertex Pharmaceuticals was unfortunately bought at previous high price.

Returns

Cumulative Returns on VRTX

23.0%


10-Year Cumulative Returns

13.5%


7-Year Cumulative Returns

17.6%


5-Year Cumulative Returns

12.6%


3-Year Cumulative Returns

What are the long-term rolling returns for VRTX?

FIve years rolling returns for Vertex Pharmaceuticals.

Which funds bought or sold VRTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
Bridgefront Capital, LLC
-
-
-212,000
-
-%
2022-11-23
Toroso Investments, LLC
ADDED
49.44
2,528,000
7,247,000
0.30%
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
265
9,000
0.01%
2022-11-22
IHT Wealth Management, LLC
NEW
-
644,000
644,000
0.05%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
6.74
428,000
4,850,000
0.15%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
43,214,000
43,214,000
0.51%
2022-11-22
CVA Family Office, LLC
-
-
14,000
80,000
0.02%
2022-11-21
FourThought Financial, LLC
-
-
112,000
484,000
0.07%
2022-11-21
Parallax Volatility Advisers, L.P.
NEW
-
324,000
324,000
-%
2022-11-21
Bray Capital Advisors
-
-
31,000
1,138,000
0.36%

1–10 of 42

Latest Funds Activity

Are funds buying VRTX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own VRTX

Vertex Pharmaceuticals News

The Motley Fool

Looking for a Once-in-a-Decade Buying Opportunity? Buy These 3 Stocks Before 2023.36 minutes ago

InvestorPlace

VRTX Fair Value

Recent SEC filings of Vertex Pharmaceuticals

View All Filings
Date Filed Form Type Document
Nov 17, 2022
4
Insider Trading
Nov 09, 2022
4
Insider Trading
Nov 03, 2022
4
Insider Trading
Oct 28, 2022
10-Q
Quarterly Report
Oct 27, 2022
8-K
Current Report
Oct 26, 2022
4
Insider Trading
Oct 20, 2022
4
Insider Trading
Oct 18, 2022
4
Insider Trading
Oct 18, 2022
4
Insider Trading
Oct 18, 2022
4
Insider Trading

Latest Insider Trading transactions for VRTX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-15
ALTSHULER DAVID
SOLD
-10,492.7
308.61
-34
EVP, Global Research and CSO
2022-11-07
ALTSHULER DAVID
ACQUIRED
244,352
187.53
1,303
EVP, Global Research and CSO
2022-11-07
ALTSHULER DAVID
SOLD
-394,859
303.038
-1,303
EVP, Global Research and CSO
2022-11-02
Sanna Bastiano
SOLD
-100,045
312.641
-320
EVP, Cell & Genetic Therapies
2022-11-01
Sanna Bastiano
SOLD FOR TAXES
-240,261
312.84
-768
EVP, Cell & Genetic Therapies
2022-10-24
Bhatia Sangeeta N.
SOLD
-192,510
310
-621
-
2022-10-18
Sanna Bastiano
SOLD
-537,860
300.313
-1,791
EVP, Cell & Genetic Therapies
2022-09-19
Biller Jonathan
ACQUIRED
-
-
5,294
EVP and Chief Legal Officer
2022-08-15
Arbuckle Stuart A
ACQUIRED
1,022,250
155.57
6,571
EVP, COO
2022-08-15
Kewalramani Reshma
SOLD
-3,565,850
305.06
-11,689
CEO & President

1–10 of 50

Reshma Kewalramani
3900
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

VRTX Income Statement

2022-09-30
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Revenues$ 2,334.3$ 1,984.1$ 6,628.0$ 5,501.8
Costs and expenses:    
Cost of sales289.4236.5797.0656.8
Research and development expenses645.0467.01,846.21,370.0
Acquired in-process research and development expenses29.026.792.9986.8
Selling, general and administrative expenses246.8198.2677.3584.9
Change in fair value of contingent consideration(2.6)1.2(59.3)(1.1)
Total costs and expenses1,207.6929.63,354.13,597.4
Income from operations1,126.71,054.53,273.91,904.4
Interest income46.21.158.63.7
Interest expense(13.7)(15.2)(43.2)(46.4)
Other income (expense), net17.242.4(133.7)(2.2)
Income before provision for income taxes1,176.41,082.83,155.61,859.5
Provision for income taxes245.9230.9652.5287.5
Net income$ 930.5$ 851.9$ 2,503.1$ 1,572.0
Net income per common share:    
Basic (in dollars per share)$ 3.63$ 3.30$ 9.78$ 6.08
Diluted (in dollars per share)$ 3.59$ 3.28$ 9.68$ 6.03
Shares used in per share calculations:    
Basic (in shares)256.5257.9255.8258.7
Diluted (in shares)259.5259.7258.7260.9
Product revenues, net    
Revenues:    
Revenues$ 2,334.3$ 1,984.1$ 6,628.0$ 5,500.8
Other revenues    
Revenues:    
Revenues$ 0.0$ 0.0$ 0.0$ 1.0

VRTX Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 9,171.5$ 6,795.0
Marketable securities599.2729.9
Accounts receivable, net1,385.21,136.8
Inventories388.2353.1
Prepaid expenses and other current assets726.9545.8
Total current assets12,271.09,560.6
Property and equipment, net1,118.71,094.1
Goodwill1,075.21,002.2
Intangible assets603.6400.0
Deferred tax assets1,162.7934.5
Operating lease assets342.7330.3
Other assets132.5110.8
Total assets16,706.413,432.5
Current liabilities:  
Accounts payable126.9195.0
Accrued expenses2,264.41,678.6
Other current liabilities218.0268.4
Total current liabilities2,609.32,142.0
Long-term finance lease liabilities442.3509.8
Long-term operating lease liabilities382.3377.4
Long-term contingent consideration127.2186.5
Other long-term liabilities115.7116.8
Total liabilities3,676.83,332.5
Commitments and contingencies0.00.0
Shareholders’ equity:  
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding0.00.0
Common stock, $0.01 par value; 500,000,000 shares authorized, 256,645,737 and 254,479,046 shares issued and outstanding, respectively2.62.5
Additional paid-in capital7,225.56,880.8
Accumulated other comprehensive income97.615.9
Retained earnings5,703.93,200.8
Total shareholders’ equity13,029.610,100.0
Total liabilities and shareholders’ equity$ 16,706.4$ 13,432.5